Thursday, May 02, 2024
Starlight Cardiovascular, Inc., a leader in pediatric cardiovascular medical devices, has received a Phase II Small Business Innovation Research (SBIR) grant from the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH).
The grant, totaling $1,999,870, will accelerate the development of its Pulmonary Flow Restrictor, designed to prevent harmful over-circulation to the lungs in infants born with Congenital Heart Disease (CHD).
CHD is the most common birth defect, affecting around 1.3 million newborns globally each year. Many infants with complex CHD require open-heart surgery, often within their first two weeks of life. Starlight Cardiovascular aims to provide a minimally invasive alternative to traditional open-chest pulmonary artery banding through its Pulmonary Artery Flow Restrictors, delivered via a small catheter.
These devices can expand to meet the evolving needs of growing infants with CHD. "Thrilled by the NIH's decision to provide significant funding to advance the development of pulmonary flow restrictors," said Chief of Cardiothoracic Surgery and Director of The Heart Center at Nationwide Children's Hospital.
"This new device not only promises to improve outcomes for infants with Hypoplastic Left Heart Syndrome undergoing hybrid procedures but also holds potential for various other applications benefiting children with Congenital Heart Disease."
The grant, with Award Number R44HL162218, is supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health. The opinions expressed in this press release are solely those of the author and do not necessarily represent the official views of the NIH.
Source: prnewswire.com
